Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics insider plans new stock sale
A holder of Mineralys Therapeutics common stock, identified in the filing as David Rodman, has filed a notice to sell 2,171 shares of common stock through Merrill Lynch on or about February 9, 2026 on the NASDAQ. The aggregate market value of this planned sale is listed as 65,585.91, with 79,139,956 common shares outstanding.
The shares to be sold were acquired the same day via an exercise of employee stock options in a broker-assisted cashless transaction with Mineralys Therapeutics, Inc. Over the prior three months, the same seller completed multiple common stock sales, including 192,715 shares for gross proceeds of 6,749,100.06 on January 5, 2026, along with several smaller transactions on other January 2026 dates.
FMR LLC and Abigail P. Johnson have disclosed a significant ownership position in Mineralys Therapeutics Inc. common stock. They report beneficial ownership of 5,017,509 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
FMR LLC has sole voting power over 5,013,931 shares and sole dispositive power over 5,017,509 shares. Abigail P. Johnson holds sole dispositive power over the same 5,017,509 shares but no voting power. The filing states the shares were acquired in the ordinary course of business and not with the purpose of influencing control of Mineralys.
Mineralys Therapeutics Inc. reported that BlackRock, Inc. has become a 5.2% beneficial owner of its common stock. As of 12/31/2025, BlackRock reports beneficial ownership of 4,113,657 shares of Mineralys common stock, with sole voting power over 4,041,593 shares and sole dispositive power over 4,113,657 shares, and no shared voting or dispositive power.
BlackRock states the securities are held by certain of its business units in the ordinary course of business and not with the purpose or effect of changing or influencing control of Mineralys. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than five percent of the total outstanding common shares.
Mineralys Therapeutics, Inc. insider Rodman David Malcom, the Chief Medical Officer, reported routine equity transactions in company stock. On January 20, 2026, he exercised a stock option for 416 shares of common stock at an exercise price of $15.44 per share and then sold 416 shares of common stock at a price of $32.1 per share.
After these trades, he beneficially owned 50,437 shares of common stock directly and 5,834 stock options directly. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, which is a pre-arranged plan designed to allow insiders to sell shares over time in a structured manner.
Mineralys Therapeutics, Inc. investor David Rodman has filed a Form 144 to sell additional common stock. The notice covers 416 shares of common stock to be sold through Merrill Lynch, with an aggregate market value of $13,353.60, and lists 79,139,956 common shares outstanding, with the planned sale on 01/20/2026 on the NASDAQ.
The filing also details prior sales of Mineralys common stock by David Rodman during the past three months, including individual transactions such as 192,715 shares sold on 01/05/2026 for gross proceeds of $6,749,100.06 and 70,037 shares sold on 01/02/2026 for $2,511,919.03, along with several smaller sales in January 2026. The seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in company stock. On January 13, 2026, he exercised stock options for 3,542 shares at $10.20 per share and 4,167 shares at $14.25 per share, receiving the same number of common shares. That day he sold 7,709 shares at $32.75 per share, followed by a sale of 11,367 shares at a weighted-average price of $32.6071 on January 14, 2026.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the reported trades, Malcom beneficially owned 50,437 shares of common stock, plus stock options for 131,042 shares and 104,167 shares that vest over time according to their grant terms.
Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 11,367 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch on the NASDAQ around 01/14/2026, with an aggregate market value of $370,645.39 and 79,139,956 shares outstanding. These shares were acquired on 01/13/2025 by exercising employee stock options for cash.
Over the past three months, the same seller has completed multiple Mineralys common stock sales, including 192,715 shares on 01/05/2026 for $6,749,100.06 and 70,037 shares on 01/02/2026 for $2,511,919.03. By signing the notice, the seller represents that he is not aware of any material adverse information about Mineralys’s current or prospective operations that has not been publicly disclosed.
Mineralys Therapeutics, Inc. insider filing shows planned stock sales by its Chief Executive Officer, Jon Congleton. On 01/12/2026, he sold 9,119 shares of common stock at a weighted-average price of $32.2083 and 7,117 shares at a weighted-average price of $33.1505, both coded as open-market sales.
The transactions were executed under a Rule 10b5-1 trading plan adopted on January 28, 2025, which is designed to pre-arrange trades. After these sales, Congleton directly beneficially owned 639,151 shares of Mineralys common stock.
Mineralys Therapeutics, Inc. reported an insider share sale by its CFO and Secretary, Adam Scott Levy. On 01/12/2026, he sold 10,758 shares of common stock in an open-market transaction at a weighted-average price of $32.1364 per share, under transaction code "S" for a sale. After this trade, he directly owned 8,638 shares of Mineralys common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Levy adopted on November 14, 2023. The filing notes that the reported price is an average and that the shares were sold in multiple trades at prices ranging from $31.90 to $32.37, with detailed trade breakdowns available on request.
Mineralys Therapeutics Chief Medical Officer trades shares under a pre-set plan. Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, reported exercising stock options for 2,170 shares of common stock on January 9, 2026 at an exercise price of $16.00 per share and for 6,348 shares on January 12, 2026 at an exercise price of $1.08 per share.
On each date, he then sold the same number of common shares, with 2,170 shares sold at $33.27 and 6,348 shares sold at a weighted-average price of $32.3162, in multiple trades between $32.01 and $32.93. After these transactions, he directly beneficially owned 61,804 shares of common stock, along with stock options covering 28,218 and 38,092 shares from two grants. All trades were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.